42
Views
7
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful treatment of a patient with refractory adult Still's disease by tacrolimus

, , , , , , & show all
Pages 167-170 | Received 31 Jul 2006, Accepted 26 Dec 2006, Published online: 02 Jan 2014

References

  • Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987;14: 1139–46.
  • Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550–60.
  • Hoshino T, Ohta A, Nakao M, Ota T, Inouchi T, Matsueda S, et al. TCR��+ T cells in peripheral blood of patients with adult Still's disease. J Rheumatol 1993;23:124–9.
  • Fujii T, Nojima H, Yasuoka S, Satoh S, Nakamura M, Kuwana M, et al. Cytokine and immunogenetic profi les in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology 2001;40:1398–404.
  • Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794–803.
  • Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388–9.
  • Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infl iximab: fi rst experiences. Ann Rheum Dis 2001;60: 55–7.
  • Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171–6.
  • Fautrel B, Sibilia J, Mariette X, Combe B, the Club Rhumatismes et Infl ammation. Tumour necrosis factor � blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64: 262–6.
  • Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still's disease refl ects a Th2 rather than a Th1 cytokine profi le. Clin Immunol 2004;112:120–5.
  • Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classifi cation of adult Still's disease. J Rheumatol 1992;19:424–30.
  • Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 2004;63: 1300–6.
  • Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 2002;3: 394–7.
  • Kuinose M, Iwagaki H, Morimoto Y, Kohka H, et al. Calcineurin antagonists inhibit interferon-gamma production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med Okayama 2000;54:201–9.
  • Fujii T, Akizuki M, Kameda H, Matsumura M, Hirakata M, Yoshida T, et al. Methotrexate treatment in patients with adult onset Still's disease-retrospective study of 13 Japanese cases. Ann Rheum Dis 1997;56:144–8.
  • Marchesoni A, Ceravolo GP, Battafarano N, Rossetti A, Tosi S, Fantini F. Cyclosporin A in the treatment of adult onset Still's disease. J Rheumatol 1997;24:1582–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.